NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 22.93% ano a ano.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 727.33M.
Avaliação Justa
O PE mais recente da empresa é -19.39, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 156.61M ações, um aumento de 4.58% em relação ao trimestre anterior.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.79.